Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Isatuximab for Desensitization or AMR in Lung Transplant
NCT05862766Phase 1Withdrawn
- Sponsor
- NYU Langone Health
- Start
- Dec 2024
- Primary completion
- Jan 2026
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of isatuximab in antibody mediated rejection (AMR) and Allosensitization (2 arms), sponsored by NYU Langone Health. Primary endpoints: Clinical Resolution (AMR episodes) at Day 28, Clinical Resolution (DSA presence) at Day 28 and 1 more. Planned start Dec 2024; status: withdrawn.
02
Drugs
isatuximab
03
Conditions
antibody mediated rejection (AMR)Allosensitization
Beyond the preview
Go deeper on NCT05862766.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05862766.